Selvaraj N, Dantes A, Limor R, Golander A, Amsterdam A
Department of Molecular Cell Biology, The Weizmann Institute of Science, 76100, Rehovot, Israel.
Endocrine. 1996 Dec;5(3):275-83. doi: 10.1007/BF02739060.
Levels of gonadotropic hormones in human sera or urine are routinely measured by radioimmunoassay or by enzyme-linked immunoassay (ELISA), which determine the immunoactivity of the hormone, but not its biological activity. We have utilized immortalized stable steroidogenic granulosa cells, which express 5-10 times more of the luteinizing hormone/chorionic gonadotropin (LH/CG) receptors than the primary cells, to develop a biological assay and radioreceptor assay for this hormone. We found that stimulation of cells expressing LH/CG receptor with increasing doses of human LH or human CG resulted in a dose-dependent increase of cAMP and progesterone with an ED(50) of 30 and 57 mlU/mL, respectively. These dose-response data served as calibration curves for measuring the gonadotropin bioactivity in human serum samples at concentrations as low as 1-5 mlU/mL. We found a close correlation between LH levels measured by enzyme immunoassay (EIA) and the in vitro bioassay in normal cycling and menopausal women, as well as in normal adult men. Also, a close correlation was found between the EIA and the in vitro biological assay of hCG in pregnant women. In addition, we have developed a radioreceptor assay (RRA) for this hormone using enriched cell membranes of the appropriate cell line, which corresponds well to both the EIA and the bioassay in human sera. Deglycosylated hCG was fully active in RRA, but failed to activated cAMP response in these cells, demonstrating the importance of the bioassay in the biologically inactive form of gonadotropins. We believe this novel in vitro bioassay of gonadotropic hormones will serve as a useful tool for a more comprehensive set of assays that will determine not only the amount, but also the possible modulation in bioactivity of the gonadotropin associated with gonadal failure and miscarriage.
人血清或尿液中的促性腺激素水平通常通过放射免疫测定法或酶联免疫吸附测定法(ELISA)进行测量,这些方法可测定激素的免疫活性,但无法测定其生物活性。我们利用永生化稳定的类固醇生成颗粒细胞,其表达的促黄体生成素/绒毛膜促性腺激素(LH/CG)受体比原代细胞多5至10倍,来开发针对该激素的生物测定法和放射受体测定法。我们发现,用递增剂量的人LH或人CG刺激表达LH/CG受体的细胞,会导致cAMP和孕酮呈剂量依赖性增加,其半数有效剂量(ED50)分别为30和57 mIU/mL。这些剂量反应数据用作校准曲线,用于测量浓度低至1 - 5 mIU/mL的人血清样本中的促性腺激素生物活性。我们发现,在正常月经周期和绝经后女性以及正常成年男性中,酶免疫测定法(EIA)测得的LH水平与体外生物测定法之间存在密切相关性。此外,在孕妇中,EIA与hCG的体外生物测定法之间也发现了密切相关性。此外,我们利用合适细胞系的富集细胞膜开发了针对该激素的放射受体测定法(RRA),该方法与人类血清中的EIA和生物测定法都非常吻合。去糖基化的hCG在RRA中具有完全活性,但在这些细胞中未能激活cAMP反应,这表明生物测定法对于促性腺激素无生物活性形式的重要性。我们相信,这种新型的促性腺激素体外生物测定法将成为一种有用的工具,用于更全面的测定,不仅可以确定促性腺激素的量,还可以确定与性腺功能减退和流产相关的促性腺激素生物活性的可能调节情况。